Experience of Intravireal Anti-Vascular Endothelial Growth Factor Therapy in Exudative Age-related Macular Degeneration. After Two Years of the Therapeutic Drug Monitoring Program

Wydanie 2/2018
str. 19 – 21

Autorzy: Marta Maciocha, Anna Święch-Zubilewicz, Agata Prokopiuk, Małgorzata Latalska, Jerzy Mackiewicz

Klinika Chirurgii Siatkówki i Ciała Szklistego Uniwersytetu Medycznego w Lublinie
Kierownik: dr hab. n. med. Jerzy Mackiewicz

Summary: 

Purpose: The aim of the study is to evaluate the efficacy of the treatment of patients with neovascular age-related macular degeneration after two years of treatment in the therapeutic drug monitoring program.

Material and Methods: 168 patients with exudative age-related macular degeneration treated in the medication program at the Department of Vitreoretinal Surgery of the Medical University were enrolled. The study group consisted of 108 women (64.3%), aged 53 to 94 years (avg. 74.1 ± 7.8) and 60 men (35.7%), aged 59 to 91 years (avg. 76.2 ± 4.0). The best corrected visual acuity for distance on the Snellen boards and central retinal thickness were studied on qualifications, the first checkpoint, at the end of the first year and at the end of the second year of the medication program.

Results: Best corrected visual acuity at the moment of qualifications was 0.3 ± 0.16 and central retinal thickness was 304 µm ± 105. At the end of the first year of the treatment best corrected visual acuity improved to 0.35 ± 0.19 and central retinal thickness was reduced to 211 µm ± 61.0. After two years of the treatment best corrected visual acuity improved to 0.41 ± 0.18 and central retinal thickness came to 211 µm ± 54.0.

Conclusions: The Therapeutic Drug Monitoring Program that provides pro re nata treatment of aflibercept and ranibizumab in the second year of treatment was effective and provides maintaining the effects gained in the first year in the treatment of neovascular age-related macular degeneration.